Abstract

AbstractAntibiotic resistance in bacteria exacerbates the issue of antimicrobial resistance. Bacteria that cause common or serious infections have evolved resistance to every new antibiotic that has been introduced into the market, to varying degrees, over several decades. Faced with this reality, one of society's most urgent needs is for new antimicrobial drugs with novel mechanisms of action. With this objective, we describe here the development of a novel set of compounds including piperazine‐ and thiophene‐based thiazolidinones(5a–i)and thiophene‐thiazolidinones(6a–i). Compounds(5a–i)and(6a–i)were developed, synthesized, and tested for their antimicrobial activity, and their structures were elucidated with the help of various analytical techniques. Compounds5aand5dshowed excellent antibacterial efficacy againstPseudomonas aeruginosa, with MICs of 50 μg/ml, whereas compounds6cand6eshowed similar potency againstStaphylococcus aureusandEscherichia coli, respectively. The antifungal efficacy of compounds5eand6iagainstCandida albicanswas outstanding (MIC = 50 μg/ml). The only compound that had excellent antifungal efficacy againstAspergillus nigerwas compound5e(MIC = 50 μg/ml). The chemico‐in silico‐biology approach could provide valuable insights into the potential of this novel hybridized scaffold for the development of promising antimicrobial agents.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call